Pharmos
Corporation to Present at JPMorgan H&Q 20th Annual
Healthcare Conference
Iselin
NJ, January 4, 2002 – Pharmos Corporation (Nasdaq:
PARS and Nasdaq Europe: PHRM) announced today it will
present to institutional investors and equity analysts
next week at the JPMorgan H&Q 20th Annual Healthcare
Conference in San Francisco on Wednesday, January 9, 2002,
at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). The
presentation will outline the Company’s progress
toward solidifying its position in the therapeutic marketplace
for neurological indications.
Core
discussion will be devoted to the pipeline of products
growing from Pharmos’ library of proprietary non-psychotropic
cannabinoid compounds (dextrocannabinoids) and their development
as treatments for various CNS and peripheral neuro-inflammatory
disorders. Progress in programs for stroke, neuropathic
pain and Parkinson’s disease will be highlighted,
and results from an animal model for acute renal ischemia
will be introduced. The presentation will also review
progress in the pivotal Phase III clinical trial of dexanabinol
for traumatic brain injury.
A
simultaneous webcast of Pharmos’ presentation will
be available at http://php4.eventsdigital.com/events/jpmhq/healthcare2002/index.html,
and will be archived for a limited time after the conference.
Pharmos
Corporation discovers, develops and commercializes novel
therapeutics to treat a range of neurological disorders
associated with inflammatory processes, such as traumatic
brain injury, stroke, neuropathic pain, Parkinson’s
disease and other CNS and peripheral neuro-inflammatory
indications.
Statements
made in this press release related to future beneficial
expectations and projections of the Company are forward-looking
and are made pursuant to the safe harbor provisions of
the Securities Litigation Reform Act of 1995. Such statements
involve risks and uncertainties which may cause results
to differ materially from those set forth in these statements.
Additional economic, competitive, governmental, technological,
marketing and other factors identified in Pharmos’
filings with the Securities and Exchange Commission could
affect such results.
back
to News Room
